What is Pharvaris N.V. (PHVS)?

Pharvaris N.V. (PHVS) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of PHVS?

The current price of PHVS is $32.82. Prices are updated in real time on Stocks360.

What is PHVS's price-to-earnings (PE) ratio?

PHVS's trailing twelve-month PE ratio is -10.89, based on current price and earnings per share data available on Stocks360.

What is PHVS's market capitalization?

PHVS's market capitalization is $2,292,926,634.00, placing it in the mid-cap tier.

Pharvaris N.V. (PHVS)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$32.82

Market Cap

$2.29B

PE (TTM)

-10.89

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

-2.46

Day Range

$31.75 – $32.86

52-wk Range

$21.02 – $43.25

Avg Volume

N/A

Volume

381.04K

Pharvaris N.V. (PHVS) is a publicly traded company in the Healthcare sector. Latest price: $32.82. Market cap $2.29B. Trailing PE -10.89. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2025-10-29 · $22.08 2026-10-28 · $32.82 (+48.64%)

Earnings

Most Recent

Aug 12, 2026

EPS $-0.81 vs est. $-0.75

Missed by $0.06

Next Earnings

Nov 11, 2026

EPS estimate $-0.82

Proprietary Signals

Signal snapshot temporarily unavailable.

About Pharvaris N.V.

Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-10.89×
P/S (TTM)	0.00×
P/B	6.66×
P/FCF (TTM)	-13.16×
EV / EBITDA	-10.09×
EV / Sales	0.00×
Earnings Yield	-8.57%
Free Cash Flow Yield	-7.60%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$1.74B
Net Income (TTM)	-$176.08M
Free Cash Flow (TTM)	-$156.00M
Net Debt	-$317.61M
Working Capital	$299.50M
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Return on Equity	-61.24%
Return on Invested Capital	-60.72%